ReviewPharmaceutics2022
Lipid and Polymeric Nanoparticles: Successful Strategies for Nose-to-Brain Drug Delivery in the Treatment of Depression and Anxiety Disorders.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Intranasal nanoemulsion for targeted medication delivery to the brain: a novel approach to treat psychotic disorder.Drug delivery and translational research · 2026Review
- Sonoselective Transfection of Glioma Endothelium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Chitosan-Based Nanoparticles for Nose-to-Brain Drug Delivery: A Real Path toward Effective CNS Therapy?ACS biomaterials science & engineering · 2026Review
- Advanced Sensing and Delivery Technologies for Nose-to-Brain Administration: From Nanocarriers to Sensor-Integrated Organ-on-Chips.Sensors (Basel, Switzerland) · 2026Review
- Intranasal administration in modulating depressive-like behavior and reconstructing treatment paradigms through neuroinflammation and neurotrophic pathways.Journal of nanobiotechnology · 2026Review
- Development, Characterization, and Evaluation of the Antidepressant Potential of Crocus sativus SLN Nasal Spray in a Drosophila melanogaster Model.Combinatorial chemistry & high throughput screening · 2026Article
- Intranasal Nano-Delivery Systems: Emerging Strategies for Central Nervous System Disease Therapeutics.International journal of nanomedicine · 2026Review
- Precision nanomedicine for anxiety: challenges, opportunities, and future directions in targeted drug delivery.Journal of food and drug analysis · 2025Review
- Polymeric nanomaterials as a drug delivery system for anticancer and antibacterial infections: a review.RSC advances · 2025Review
- Recent advances in biomimetic nanodelivery systems for the treatment of depression.Materials today. Bio · 2025Review
- Advancements in Nanocarrier Systems for Nose-to-Brain Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cyclodextrin-Based Drug Delivery Systems for Depression: Improving Antidepressant Bioavailability and Targeted Central Nervous System Delivery.Pharmaceutics · 2025Review
- Exploring chitosan nanoparticles for enhanced therapy in neurological disorders: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Preclinical Insights into the Role of Kir4.1 in Chronic Pain and Depression: Mechanisms and Therapeutic Potential.Biomolecules · 2025Review
- Article
- A Review on Lipid-based Nanoformulations for Targeting Brain through Non-invasive Nasal Route.Pharmaceutical nanotechnology · 2025Review
- Integrative approaches to depression in end-stage renal disease: insights into mechanisms, impacts, and pharmacological strategies.Frontiers in pharmacology · 2025Review
- Advancements in Nanotherapeutics for the Treatment of Depression via Intranasal Pathway: A Review.International journal of nanomedicine · 2025Review
- [Development of a new platform for testing antiviral drugs using coronavirus-infected human nasal mucosa organoids].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms.Journal of biological engineering · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intranasal administration has gained an increasing interest for brain drug delivery since it allows direct transport through neuronal pathways, which can be quite advantageous for central nervous system disorders, such as depression and anxiety. Nanoparticles have been studied as possible alternatives to conventional formulations, with the objective of improving drug bioavailability. The present work aimed to analyze the potential of intranasal nanoparticle administration for the treatment of depression and anxiety, using the analysis of several studies already performed. From the carried-out analysis, it was concluded that the use of nanoparticles allows the drug's protection from enzymatic degradation, and the modulation of its components allows controlled drug release and enhanced drug permeation. Furthermore, the results of in vivo studies further verified these systems' potential, with the drug reaching the brain faster and leading to increased bioavailability and, consequently, therapeutic effect. Hence, in general, the intranasal administration of nanoparticles leads to a faster onset of action, with increased and prolonged brain drug concentrations and, consequently, therapeutic effects, presenting high potential as an alternative to the currently available therapies for the treatment of depression and anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.